Qualigen Therapeutics, Inc.
https://www.qualigeninc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Qualigen Therapeutics, Inc.
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Tech Transfer Roundup: Tmunity Targets Pediatric Glioma With UCSF-Discovered TCR Therapy
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- NanoSynex Ltd.
- Ritter Pharmaceuticals, Inc.
- Qualigen Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice